Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA-PDT with fluorescence diagnosis for field cancerization in actinic keratosis
ChiCTR2400092654Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 5-aminolevulinic acid in actinic keratosis (AK), sponsored by West China Hospital of Sichuan University. Primary endpoint: Complete remission rate of AK lesions 3 months after the last therapy. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on ChiCTR2400092654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092654.